Biogen (BIIB) and Eisai Announce FDA's 3-Month Extension of Review Period for BLA for Aducanumab

Go back to Biogen (BIIB) and Eisai Announce FDA's 3-Month Extension of Review Period for BLA for Aducanumab
BIOGEN IDEC Inc. (NASDAQ: BIIB) Delayed: 275.61 --0 (-0%)
Previous Close $275.61    52 Week High $333.65 
Open $275.61    52 Week Low $223.02 
Day High $275.61    P/E 35.29 
Day Low $275.61    EPS $7.81 
Volume 174